Prof. Bernd Kasper, MD, PhD, studied Medicine at the University of Heidelberg and received his MD degree from Heidelberg University in 2000. In 2001, he finalized his thesis at the German Cancer Research Centre (DKFZ) in Heidelberg, dealing with new treatment strategies for chronic myelogenous leukemia patients using the tyrosine kinase inhibitor imatinib. To deepen his training, he stayed in London (Imperial College School of Medicine, Hammersmith Hospital, Department of Haematology), Brussels (Jules Bordet Institute, Medical Oncology Clinic) and South Kerala, India. In 2007 and 2008, he specialized in Internal Medicine and Medical Haematology/Oncology at the Department of Internal Medicine V at the University of Heidelberg. Currently, he works at the Sarcoma Unit at the Mannheim Cancer Center (MCC), University of Heidelberg. Prof. Kasper has a life-time professional dedication to patient care and research in soft tissue sarcomas (STS), desmoid-type fibromatosis (DF) and gastrointestinal stromal tumors (GIST).
He is head of the study center of the German Interdisciplinary Sarcoma Group (GISG). He serves as the current Chair of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) and is member of the Board of Directors of the Connective Tissue Oncology Society (CTOS). Prof. Kasper has authored around 100 scientific publications. He is a dedicated board member to patient organizations dealing with STS, DF and GIST on the national and international level such as SPAGN, NLMSF, and the DTRF.
